Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
CONX (CONXU)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

Prelude Therapeutics Incorporated (PRLD)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Their lead product candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5, or PRMT5. The potency and selectivity of their product candidates is supported by preclinical data demonstrating nanomolar inhibition of PRMT5 and no inhibition of related enzymes at 1,000 times higher concentration of their product candidates. They are currently advancing their first clinical candidate, PRT543, in a Phase 1 clinical trial in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies. Interim Phase 1 results indicate dose-dependent increases in exposure and target engagement, and they have observed early signs of clinical activity, including a confirmed complete response, or CR, in a patient with HRD+ high grade serous ovarian cancer. A complete response is defined as the disappearance of all target lesions. While they will need to enroll and demonstrate objective responses in additional patients to support further development and potential approval by the FDA or other regulatory authorities, and while such approval is not guaranteed, they are encouraged by the clinical activity to date. They anticipate enrollment in expansion cohorts in their ongoing Phase 1 trial beginning in the second half of 2020 and expect clinical data beginning in the first half of 2021.
Industry
Pharmaceuticals
CEO CFO
Krishna Vaddi Brian Piper
Employees Founded
51 2016

Contacts

Address: 200 Powder Mill Road Wilmington, Delaware 19803

Telephone: (302) 467-1280

Web page: https://www.preludetx.com/

IPO information

Expected Date 9/25/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $765.0
Revenues (MM) $0
Net Income (Loss) (MM) $-37.7

Voting

What do you think will happen with the PRLD share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.3
Shares Revised (MM) 8.3
Expected offer amount (MM) $149.4
Realized offer amount(MM) $157.7
Underwriters
Morgan Stanley/ Goldman Sachs/ BofA Securities
CO-Managers
-

Sector: Healthcare

Tweets about $PRLD

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats